UnknownPhase 2NCT04659434

Sintilimab Plus R-GemOx as Second-line Salvage Therapy in Patients With R/R DLBCL

Studying Epstein-Barr virus-positive diffuse large B-cell lymphoma

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Qian Wenbin
Principal Investigator
wenbin Qian
2nd Affiliated Hospital, School of Medicine, Zhejiang University
Intervention
Sintilimab(drug)
Enrollment
51 enrolled
Eligibility
18-80 years · All sexes
Timeline
20202025

Study locations (1)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT04659434 on ClinicalTrials.gov

Other trials for Epstein-Barr virus-positive diffuse large B-cell lymphoma

Additional recruiting or active studies for the same condition.

See all trials for Epstein-Barr virus-positive diffuse large B-cell lymphoma

← Back to all trials